S3300

The ANCHOR Act of 2025 amends Title XIX of the Social Security Act, specifically Section 1902, to establish a state option for extending Medicaid coverage. This bill targets uninsured individuals with incomes up to 100% of the poverty line who have a qualifying condition such as serious mental illness, serious emotional disturbance, opioid use disorder, or stimulant use disorder. This is a direct expansion of the Medicaid eligible population, creating a new and substantial funding mechanism for behavioral health services. The money trail for this legislation flows directly from federal and state Medicaid programs to healthcare providers and managed care organizations. States opting into this program will receive federal matching funds for covering these newly eligible individuals. This means increased reimbursement for diagnostic services, treatment programs, and ongoing care for mental health and substance use disorders. Companies that operate certified community behavioral health clinics (CCBHCs), institutions for mental diseases (IMDs), and those providing diagnostic testing for substance use disorders are directly positioned to capture this funding. Managed care organizations (MCOs) that administer state Medicaid programs will also see an increase in their covered lives and associated premiums. Historically, expansions of Medicaid eligibility have led to increased utilization of healthcare services and revenue growth for providers. For example, following the Affordable Care Act's Medicaid expansion in 2014, states that expanded saw a significant increase in Medicaid enrollment and a corresponding boost in revenue for hospitals and MCOs operating in those states. While specific stock movements are complex, companies with significant Medicaid exposure generally benefited. For instance, in the year following the ACA's full implementation in 2014, major MCOs like UnitedHealth Group ($UNH) and Centene ($CNC) saw their stock prices rise by approximately 25% and 40% respectively, driven in part by increased enrollment. Specific winners include large diagnostic companies like LabCorp ($LH) and IQVIA ($IQV) due to increased demand for drug testing and mental health assessments. Managed care organizations such as UnitedHealth Group ($UNH), CVS Health ($CVS) (through Aetna), Humana ($HUM), Molina Healthcare ($MOH), and Centene ($CNC) will benefit from expanded enrollment and increased premium revenue. Behavioral health providers, including those operating inpatient and outpatient facilities, will see higher patient volumes and reimbursement. Companies like Magellan Health (now part of Centene, $CNC) and Acadia Healthcare ($ACHC) (though Acadia is not directly named in the bill text, it operates IMDs) are positioned to gain. Staffing companies like AMN Healthcare ($AMN) will also see increased demand for mental health professionals. There are no clear losers from this bill, as it expands access and funding without imposing new burdens or restrictions on existing services. This bill has been introduced in the Senate and referred to the Committee on Finance. The next step is committee consideration, including potential hearings and markups. If it passes the Committee, it will proceed to a full Senate vote. If passed by the Senate, it would then move to the House of Representatives for consideration. Given Senator Blackburn's sponsorship and the bipartisan nature of addressing mental health and substance use disorders, the bill has a moderate chance of advancing, though the timeline for passage is uncertain and could extend into 2026.